Supply Chain

Agreement provides pharma firms with an RWD and commercialization solution

The solution is a combination of cold chain logistics, serialization compliance and distribution

Today’s ideal pharma third-party logistics (3PL) provider brings the right mix of physical assets, internal expertise, data analytics and strategic partnerships to function as a seamless extension of a manufacturer’s internal operations—no matter what disruptions arise

The growing complexity and demand in distribution amid the pandemic present unique technology opportunities for third-party logistics providers

A conversation with Michael Abrams, co-founder and managing partner, Numerof & Associates

As more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch

Examining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals

Can technology really build trust in pharmaceutical supply chains?

Quris’s system can help predict clinical safety, AI firm notes

Magellan Rx Management and Zipline have collaborated on a pilot project to deliver prescription medications directly to patients’ homes via autonomous aircraft. Magellan Rx CEO Mostafa Kamal discusses how this innovative delivery method aims to reduce barriers to care.

Collaboration, the companies note, is expected to further engage patients

Action offers the fulfillment of a critical part of the Drug Supply Chain Security Act (DSCSA)

A sit-down with members of the Deloitte team, who discuss the findings of the company’s yearly research and development report

USP study reveals urgency to make changes, with additional concerns coming to light amid times of crisis

Logistics provider’s investment will develop distribution area by an additional 27%

Acquisition expands Medable’s global engineering talent and gives company a third location in Europe

CDMO will use its BFS knowledge to support production out of its Kaysersberg, France plant

Following a November FDA public meeting, HDA reiterates the objections it had to guidance FDA issued in mid-2021 under the Drug Supply Chain Security Act (DSCSA)

The benefits of establishing an in-depth go-to-market commercialization strategy for a new CGT in the beginning of clinical trials

Merger with Phlexglobal expands provider’s technological capabilities

Expansion of the collaboration features a reduction in carbon dioxide emissions

Integrated system intends to accelerate enrollment by strengthening relationship between hub patient services and providers

Anticipated yearly production is 2 million units

In a civil action, Gilead alleges an extensive, transnational counterfeiting ring of HIV and other drugs